ArticleThe American journal of case reports2026
Case Report: Botulinum Toxin Type A Injection for Bruxism Following Left Basal Ganglia Hemorrhage.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Post‑stroke bruxism is an underrecognized complication that may impair oral function, cause orofacial pain, and negatively impact rehabilitation outcomes. Botulinum toxin type A (BoNT‑A) has been reported for bruxism, but its application in post‑stroke populations remains sparsely documented. This case describes the assessment and treatment of bruxism following cerebral hemorrhage, utilizing the Standardized Tool for the Assessment of Bruxism (STAB) as a structured multidimensional framework. CASE REPORT A 40-year-old man developed bruxism during recovery from a massive left hemispheric intracerebral hemorrhage after decompressive craniectomy and hematoma evacuation. About 3 months after admission, he began to exhibit bilateral masseter muscle hypertrophy with marked tenderness, temporomandibular joint pain, and drooling from the right mouth corner, with no prior history of bruxism. STAB-based evaluation yielded the following Axis A findings: Subject-based assessment revealed nocturnal grinding reported by caregivers. Clinically based assessment revealed bilateral masseter hypertrophy, tenderness on palpation, and dental wear. Instrument-based assessment (surface electromyography used for injection guidance) confirmed increased masseter muscle activity at rest and during clenching. Symptoms were refractory to occlusal splint therapy combined with hot compresses. At 48 hours after electromyography-guided injection into the bilateral masseter muscles (50 U per side, divided into 3 sites per side), muscle tension and tenderness were markedly reduced, and clinical improvement persisted at 6-month follow-up. CONCLUSIONS In this single case, BoNT‑A injection was temporally associated with symptom relief in post-stroke bruxism. STAB provided a structured multidimensional assessment framework. These descriptive findings have limited generalizability. Controlled studies are needed to establish the efficacy and safety of this intervention in the post‑stroke population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.